Jupiter Neurosciences highlights advancement of JOTROL

Jupiter Neurosciences (JUNS) spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL, over conventional resveratrol formulations. Resveratrol is one of the world’s most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has proven elusive due to the molecule’s extremely poor bioavailability and dose-limiting gastrointestinal side effects. JOTROL was developed specifically to overcome these critical limitations. In a Phase I clinical trial, JOTROL achieved a nine-fold increase in bioavailability compared to traditional resveratrol, without the GI toxicity seen at high doses. This proprietary formulation enables systemic therapeutic dosing with significantly reduced pill burden and enhanced tolerability. Key Differentiators: Approximately 9 times higher bioavailability at peak plasma concentration versus naive resveratrol; No GI side effects observed at therapeutic levels; Secured intellectual property in the U.S., EU, China, Japan, and Hong Kong through 2036; Demonstrated ability to reach the central nervous system by passing the blood brain barrier, a critical factor for diseases such as Parkinson’s, Alzheimer’s, and MELAS. JOTROL is currently advancing toward a Phase IIa trial in Parkinson’s Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor functions. The same delivery technology is also being used in Jupiter’s Nugevia consumer product line, launching in Q3 2025 with targeted formulations focused on cognitive health, mitochondrial energy, and skin vitality.